Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · IEX Real-Time Price · USD
8.51
0.11 (1.31%)
At close: May 20, 2022 4:00 PM
8.93
0.42 (4.94%)
After-hours:May 20, 2022 4:51 PM EDT

Company Description

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.

It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.

Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.
CountryUnited States
Founded2019
IPO DateJun 18, 2021
IndustryBiotechnology
SectorHealth Care
Employees170

Contact Details

Address:
3675 Market Street
Philadelphia, PA 19104
United States
Phone267 817 5790

Stock Details

Ticker SymbolIPSC
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$20.00
CIK Code1850119

Key Executives

NamePosition
Dr. Osvaldo Flores Ph.D.President, Chief Executive Officer and Director
Dr. Adrienne Farid Ph.D.Chief Operations Officer
Dr. Luis BorgesChief Scientific Officer
Douglas Carr CPAVice President of Finance and Operations and Secretary
Dr. Gregory Russotti Ph.D.Chief Technology Officer
Kenneth J. Dow J.D.Head of Legal and Compliance
Dr. Shane Williams Ph.D.Chief People Officer
Dr. Michael C. DiemChief Business Officer
Dr. Hyam I. Levitsky M.D.President of Research & Development
Mark WalletHead of Immunology and Vice President

Latest SEC Filings

DateTypeTitle
May 10, 20228-KCurrent report
Apr 21, 2022DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 21, 2022DEF 14AOther definitive proxy statements
Apr 13, 20228-KCurrent report
Mar 17, 2022S-8Securities to be offered to employees in employee benefit plans
Mar 17, 202210-KAnnual report [Section 13 and 15(d), not S-K Item 405]
Mar 17, 20228-KCurrent report
Feb 11, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 11, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
Feb 10, 2022SC 13GStatement of acquisition of beneficial ownership by individuals
View All SEC Filings